SENP2 and breast cancer: The results unequivocally indicated that ERK2 SUMOylation was elevated by the miR-145-5p mimic and weakened by the miR-145-5p inhibitor (Fig. 6I), indicating that miR-145-5p down-regulates the SENP2-ERK2 axis in breast cancer cells.